International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus

Arthritis Care and Research

Volumn 65, Issue 9, 2013, Pages 1416-1423

  Hollander, Matthew C ^a   Sage, Jessica M ^b   Greenler, Alexandria J ^b   Pendl, Joshua ^b   Avcin, Tadej ^c   Espada, Graciela ^d   Beresford, Michael W ^e   Henrickson, Michael ^b   Lee, Tsz Leung ^f   Punaro, Marilynn ^g   Huggins, Jennifer ^b   Stevens, Anne M ^a   Klein Gitelman, Marisa S ^h   Brunner, Hermine I ^b  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAEMOPHILUS INFLUENZAE VACCINE; HYDROXYCHLOROQUINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CARDIOVASCULAR RISK; CHILD CARE; CHILDHOOD DISEASE; CLINICAL EVALUATION; CONSENSUS; DISEASE SURVEILLANCE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE QUALITY; HEALTH EDUCATION; HUMAN; HYPERTENSION; LABORATORY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL CARE; NEUROPSYCHIATRY; PATIENT CARE PLANNING; PATIENT COUNSELING; PREVENTIVE MEDICINE; QUESTIONNAIRE; SAFETY; SYSTEMIC LUPUS ERYTHEMATOSUS;

CONSENSUS; HUMANS; INTERNATIONALITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUALITY INDICATORS, HEALTH CARE; QUESTIONNAIRES;

EID: 84883327680     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21998     Document Type: Article

References (34)

1. Rubin HR, Pronovost P, Diette GB,. The advantages and disadvantages of process-based measures of health care quality. Int J Qual Health Care 2001; 13: 469-74.
2. Passo MH, Taylor J,. Quality improvement in pediatric rheumatology: what do we need to do? Curr Opin Rheumatol 2008; 20: 625-30.
3. Kavanaugh P, Adams W, Wang C,. Quality indicators and quality assessment in child health. Arch Dis Child 2009; 94: 458-63.
4. Institute of Medicine (US), Committee on Quality of Healthcare in America. Crossing the quality chasm: a new health system for the 21st century. Consensus report. Washington, DC: NetLibrary; 2001.
5. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011; 63: 10-6.
6. Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al, and the Systemic Lupus Erythematosus Quality Indicators Project Expert Panels. A quality indicator set for systemic lupus erythematosus. Arthritis Rheum 2009; 61: 370-7.
7. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Cervera R, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011; 10: 383-8.
8. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
9. Silva CA, Avcin T, Brunner HI,. Taxonomy for systemic lupus erythematosus with onset before adulthood [review]. Arthritis Care Res (Hoboken) 2012; 64: 1787-93.
10. Mina R, Brunner HI,. Pediatric lupus: are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010; 36: 53-80.
11. Silva CA, Terreri MT, Aikawa NE, Carvalho JF, Pileggi GC, Ferriani VP, et al. Vaccination practice in children with rheumatic disease. Rev Bras Reumatol 2010; 50: 351-61.
12. Brunner HI, Klein-Gitelman MS, Ying J, Tucker LB, Silverman ED,. Corticosteroid use in childhood-onset systemic lupus erythematosus: practice patterns at four pediatric rheumatology centers. Clin Exp Rheumatol 2009; 27: 155-62.
13. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C,. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One 2011; 6: e20476.
14. Dillman D, Smyth J, Christian L,. Internet, mail, and mixed-mode surveys: the tailored design method. 3rd ed. Ann Arbor (MI): University of Michigan, Wiley & Sons; 2008.
15. Brunner HI, Mina R, Pilkington C, Beresford MW, Reiff A, Levy DM, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63: 1213-23.
16. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
17. Gilliam BE, Ombrello AK, Burlingame RW, Pepmueller PH, Moore TL,. Measurement of autoantibodies in pediatric-onset systemic lupus erythematosus and their relationship with disease-associated manifestations. Semin Arthritis Rheum 2012; 41: 840-8.
18. Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, et al. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus 2010; 19: 146-57.
19. Heijstek MW, Ott de Bruin LM, Borrow R, van der Klis F, Kone-Paut I, Fasth A, et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League Against Rheumatism evidence-based recommendations. Autoimmun Rev 2011; 11: 112-22.
20. Madhok R, Wu O,. Systemic lupus erythematosus. Clin Evid (Online) 2009; 2009: 1123.
21. Shinjo SK, Bonfa E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, et al, on behalf of the Grupo Latino Americano de Estudio del Lupus Eritematoso (GLADEL). Antimalarial treatment may have a time-dependent effect on lupus survival: data from a Multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855-62.
22. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al, on behalf of the CARRA SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 375-83.
23. Bishop N, Braillon P, Burnham J, Cimaz R, Davies J, Fewtrell M, et al. Dual-energy x-ray absorptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD pediatric official positions. J Clin Densitom 2008; 11: 29-42.
24. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, et al. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1966-73.
25. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C,. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008; 47: 920-3.
26. Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM,. Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 2009; 155: 260-5.
27. Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Nadel H, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32: 729-33.
28. Brunner HI, Feldman BM, Bombardier C, Silverman ED,. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1354-60.
29. Ruperto N, Pistorio A, Ravelli A, Hasija R, Guseinova D, Filocamo G, et al. Criteria to define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol 2011; 67 Suppl: 125-31.
30. Petersson IF,. Evolution of team care and evaluation of effectiveness. Curr Opin Rheumatol 2005; 17: 160-3.
31. Hersh A, von Scheven E, Yelin E, Medscape. Adult outcomes of childhood-onset rheumatic diseases. Nat Rev Rheumatol 2011; 7: 290-5.
32. Boros CA, Bradley TJ, Cheung MM, Bargman JM, Russell JL, McCrindle BW, et al. Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: 575-81.
33. Tucker LB, Cabral DA,. Transition of the adolescent patient with rheumatic disease: issues to consider. Rheum Dis Clin North Am 2007; 33: 661-72.
34. Hersh AO, Pang S, Curran ML, Milojevic DS, von Scheven E,. The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J 2009; 7: 13.